Illumina makes the machines that read DNA
machines that read DNA
used up on every run
its buyers
Illumina sells machines that read DNA, and every run uses chemicals only it sells. Hospital, commercial and research labs buy them, with no customer above 10% of sales.
Chemicals used per run are two thirds
The machine is sold once; the chemicals are bought again on every run.
The machine once, the chemicals every run
Each machine placed brings years of chemical sales, which only Illumina makes for it.
Hospital tests are proven on its chemistry
of volume on its newest machine
paid for a rival's patents
Each hospital test is proven on one machine's chemistry, so moving to a rival means repeating the accuracy runs and paperwork while patients wait.
Roche has launched a sequencer
Listed rivals: ROP.SW
None is yet approved for hospital diagnosis, which is where Illumina's growth comes from.
Flat sales for years, profit rebuilt by cuts
Profit came back mostly as GRAIL was spun off and costs were cut, not from growth.
Cancer care is the big hospital use
The share rose for every cancer type studied, but nobody publishes how many new diagnoses are advanced.
An Agilent veteran returned it to growth
They spun out GRAIL and brought back growth, but 2025 still fell short.
Doctors read tumours' DNA to choose treatment
Doctors now read a tumour's DNA to choose the right drug. Hospitals buying more tests is offsetting weaker spending by research labs.
A purchase and currency flatter the growth
- Reported growth speeds upLooks like recovery.
- A purchase adds salesBought, not grown.
- Currency adds moreA weak dollar.
- A third comes offPer its own table.
The company's own table strips a third out of headline growth.
Profit target beaten, outlook raised
Mixed quarter
The shares doubled in a year, helped by joining the S&P 500 on 21 September, when index funds had to buy.
Compounding again, or flattered?
Hospitals replaced lost sales and it compounds again
The speed-up is flattered by a purchase and currency
We are wrong if hospital chemicals keep growing 15% or more through 2027.
The price sits above even our sunny case
below $68.72
above $103
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
Roche's rival is the biggest threat
Research only, for now.
Research chemicals fell.
Not yet taken.
Where it settles.
China stays closed, and cheaper genomes from rivals could pull prices down.
February brings the 2027 forecast
Fourth-quarter 2026 results and the 2027 forecast, 4 February. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The DNA reading standard, priced as if recovery lasts
below $68.72
above $103
UnattractiveHigh conviction
Illumina's machines read DNA, and every run uses chemicals only it sells. Sales grow again, led by hospitals, but a third of headline growth was a purchase and currency, and Roche has launched a rival.